
Kisqali (ribociclib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) to be used in combination with tamoxifen or an aromatase inhibitor (AI) in the frontline treatment of pre- or perimenopausal women who have hormone receptor-positive HER2-negative advanced or metastatic breast cancer.




